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In Brief
Murgia et al. use mass spectrometry-
based proteomics to dissect the
pathological mosaicism of compensated
COX+ fibers and decompensated COX
fibers in mitochondrial myopathy. On this
single-cell level, COX fibers show
protean adaptive responses. These
findings reveal compensatory
mechanisms in muscle fibers struggling
with energy shortage and metabolic
stress.
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https://doi.org/10.1016/j.celrep.2019.11.055SUMMARY
The mosaic distribution of cytochrome c oxidase+
(COX+) and COX muscle fibers in mitochondrial
disorders allows the sampling of fibers with compen-
sated and decompensated mitochondrial function
from the same individual. We apply laser capture
microdissection to excise individual COX+ and
COX fibers from the biopsies of mitochondrial
myopathy patients. Using mass spectrometry-based
proteomics, we quantify >4,000 proteins per patient.
While COX+ fibers show a higher expression of respi-
ratory chain components, COX fibers display pro-
tean adaptive responses, including upregulation of
mitochondrial ribosomes, translation proteins, and
chaperones. Upregulated proteins include C1QBP,
required for mitoribosome formation and protein
synthesis, and STOML2, which organizes cardioli-
pin-enriched microdomains and the assembly of
respiratory supercomplexes. Factoring in fast/slow
fiber type, COX slow fibers show a compensatory
upregulation of beta-oxidation, the AAA+ protease
AFG3L1, and the OPA1-dependent cristae remodel-
ing program. These findings reveal compensatory
mechanisms in muscle fibers struggling with energy
shortage and metabolic stress.INTRODUCTION
Mitochondrial disorders are multisystem diseases characterized
bydefective assembly and function of the respiratory chain.Muta-
tions of both mtDNA and nuclear DNA (nDNA) are leading causes
of these disorders, for a total prevalence of adult mitochondrial
disease of 1 in 4,300 (Gorman et al., 2015). The humanmitochon-
drial genomeconsists of 37 genes encoding 13 key proteins of the
respiratory chain, 2 rRNAs, and 22 mitochondrial tRNAs (Schon
et al., 2012). The vast majority of mitochondrial proteins are, how-Cell Repor
This is an open access article under the CC BY-Never, encoded by the nDNA, which is why the corresponding dis-
orders are inherited in a dominant, recessive, or X-linked manner
(Spinazzola and Zeviani, 2009). Age-associated neurodegenera-
tion, as in Parkinson andAlzheimer disease, aswell as aging itself,
has been associated with mitochondrial dysfunction (Lightowlers
et al., 2015). Next-generation sequencing has extended the reper-
toire and greatly improved the diagnosis of mitochondrial disor-
ders (Alston et al., 2017), but the underlying pathophysiological
mechanisms are still poorly understood.
In most mtDNA-associated diseases, such as chronic
progressive external ophthalmoplegia (CPEO), mitochondrial
encephalomyopathy with lactic acidosis and stroke-like epi-
sodes (MELAS), and myoclonus epilepsy with ragged red fibers
(MERRFs), skeletal muscle shows a pathological mosaicism at
the level of its single cellular units, muscle fibers. This is apparent
using the combined cytochrome c oxidase/succinate dehydro-
genase (COX/SDH) histochemical staining, a common diag-
nostic test. Decompensated fibers are COX but retain the
blue SDH stain, which reflects the activity of complex II, the
only respiratory complex entirely encoded by nDNA, and is
thus unaffected by mutations of mtDNA. Compensated COX+
fibers stain brownish as a result of preserved COX function
(Figure 1A). The transition from the COX+ to the COX state de-
pends on the proportion ofmutant versuswild-typemtDNA in the
fiber (heteroplasmy), the threshold being mutation dependent
but mostly 60% mutant mtDNA (Alston et al., 2017).
This pathological mosaicism is superimposed onto the physio-
logical mosaic of different fiber types,which characterizes human
skeletalmuscle, one slowand two fast (2A and 2X), eachwith spe-
cific contractile and metabolic properties. In humans, slow fibers
have more mitochondria than do fast fibers (Murgia et al., 2017).
Here, we investigated how mitochondrial disease alters the
fiber proteome and how different fiber types cope with compro-
mised respiratory chain activity. The mosaicism of COX+ and
COX fibers offers the unique opportunity to investigate disease
mechanisms at the cellular level. To this aim, we generated a
proteomic workflow for a rapid, robust, and deep analysis of
fiber heterogeneity from patient biopsies using laser capture
microdissection (LCM) to separate COX+ and COX fibers (Fig-
ure 1A). Examples of a combination of LCM with proteomicsts 29, 3825–3834, December 17, 2019 ª 2019 The Author(s). 3825
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Proteomic Workflow for the Anal-
ysis of Muscle Biopsies in Mitochondrial Dis-
eases
(A) Left panel, mosaic of COX+ fibers (brown) and
COX fibers (blue). The COX fiber labeled with an
asterisk is re-identified in an unstained serial section
and laser captured (right panel). Bar, 100 mm.
(B) Muscle biopsies (right panel) and pooled sam-
ples for library generation (left panel) are processed
in parallel based on the in-StageTip (iST) protocol
(Kulak et al., 2017). Patient samples are directly
measured, library samples are fractionated to
generate the ‘‘matching library’’ before liquid chro-
matography-(LC)-MS/MS.
(C) Proteins quantified in the dataset, illustrating the
gain obtained by matching to the libraries or be-
tween samples only (match samples).
(D) Coverage of different mitochondrial annotations
(GO) in the single-fibers dataset, expressed as
the percentage of corresponding terms annotated in
the human genome (protein numbers are shown in
the bar segments).
See also Figures S1 and S2 and Tables S1, S2,
and S3.exist in the literature in other types of myopathies, such as filami-
nopathies, desminopathies, and other myofibrillar myopathies
(Feldkirchner et al., 2013; Kley et al., 2013; Maerkens et al.,
2013). Exploiting recent advances in sample preparation and
proteomic technology applied to skeletal muscle (Kulak et al.,
2014), we quantify >2,000 proteins from 20 individual fiber cryo-
sections and >4,000 per patient (see Figure S1), uncovering fiber
type-specific adaptive responses to disease, whichwould not be
distinguishable in a total lysate.
RESULTS
Workflow for the Proteomic Analysis of Muscle Biopsies
in Mitochondrial Disorders
We fractionated human muscle lysate and cultured myoblasts
using a recently described ‘‘loss-less’’ nano-fractionator (Kulak
et al., 2017). The resulting peptide libraries allowed us to over-3826 Cell Reports 29, 3825–3834, December 17, 2019come the dynamic range of the skeletal
muscle proteome. Using the ‘‘match be-
tween runs’’ feature of the MaxQuant soft-
ware (Cox and Mann, 2008; Tyanova et al.,
2016a), we transferred identifications from
the peptide libraries to the patients’ sam-
ples (Figure 1B) (Deshmukh et al., 2015).
We then optimized sample preparation in
a single reaction vessel to minimize sample
loss, contamination, and handling time
(Kulak et al., 2014). We could measure
>4,000 proteins per patient and 2,440 ±
350 proteins on average in single fibers
(Figures 1C and S1A; Table S1).
Fractions separation yielded approxi-
mately 75% of all peptides in%4 fractions
and up to 25% in 1 fraction (Figure S1B).We quantified 5,200 proteins (42,000 peptides) in the lysate,
spanning >7 orders of magnitude. The most intense quartile
was specifically enriched in myosin and ATP synthase com-
plexes and the least intense in exosome and RNA-processing
proteins (Figure S1C; Table S2). The myoblast lysate yielded
8,600 proteins (74,600 peptides), with gluconeogenesis and pro-
teasome annotations enriched in the first quartile and DNA re-
combinase annotations in the last quartile. Myoblasts had higher
proteome coverage than muscle lysate due to lower proteome
dynamic range (Figures S1C and S1D; Table S3; Deshmukh
et al., 2015).
Abundant proteins, such as those of the respiratory chain and
the tricarboxylic acid (TCA) cycle, were directly identified by
tandem mass spectrometry (MS/MS), whereas potentially dis-
ease-relevant protein classes such as those of mitochondrial
translation reached high coverage (93%) only through matching
to the libraries (Figure 1D).
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Figure 2. Expression of Respiratory Chain
Complexes in COX+ and COX Fibers
The subunits of each complex were subdivided
based on gene localization in nDNA (left) or mtDNA
(right). The statistical significance was determined
for each protein in 3 technical replicates of 3
patients by Student’s t test. Complexes with a
majority of subunits with significant expression
differences report the p value indicated by *p <
0.05 or **p < 0.01. Boxplots are superimposed
onto the mean of individual proteins. Boxes the
show median and 25th and 75th percentiles;
whiskers show the SDs. Protein expression shows
LFQ values.
(A) Expression of COX subunits.
(B) Expression of complex I subunits.
(C) Expression of complex II subunits (all nDNA
encoded).
(D) Expression of complex III subunits.
(E) Expression of ATP synthase subunits.
(F) Median expression of all respiratory chain
subunits encoded by nDNA and mtDNA in 3 pa-
tients. Values represent the analysis of technical
triplicates of 3 subjects.
See also Figures S3 and S4.Technical replicates showed Pearson correlation coefficients
of 0.98 (Figure S2). Pooled COX+ and COX fibers of the
same individual (yellow squares) showed higher correlation
(0.88–0.95) compared to those of different individuals (0.76–
0.86). Correlations were on average lower in single fibers.
Expression of Respiratory Complexes andMitochondrial
Biogenesis Factors in COX+ and COX Fibers
Using LCM to cut individual fibers from 10-mm sections, we
obtained separate pools of 100 COX+ and 100 COX fibers
from each of 3 different patients (Figure 1A; Table S4). Pools of
sections prevent sampling biases, such as different fiber type
composition leading to different mitochondrial content (Table
S5). We quantified 73 of 95 proteins Gene Ontology (GO)
annotated to the respiratory chain and ATP synthase in humans.
Classifying the respiratory chain subunits based on their gene
localization in mtDNA and nDNA, we analyzed their expression
in COX and COX+ fiber pools. Of 13 COX subunits quantified,
7 were significantly more abundant in COX+ than in COX fibers
(p < 0.05), confirming that proteomics reads out the diagnostic
histochemical difference (Figure S3). COX subunits encoded
by mtDNA were significantly more expressed in COX+ fibers
(p < 0.01) (Figure 2A). For complex I, 24 of 45 subunits quantifiedCell Reportswere higher in COX+ fibers than in COX
fibers (p < 0.05), with the 3 subunits of
mtDNA origin displaying very high signifi-
cance (p < 104) (Figures 2B and S3).
Three of 4 subunits of SDH/complex II, a
histological marker of mitochondrial con-
tent, were also highly expressed in COX+
(Figures 2C and S3). Four complex III sub-
units weremore abundant in COX+ than inCOX fibers, but overall the expression was similar. The mtDNA-
encoded subunit MT-CYB was higher in COX+ without reaching
statistical significance (Figures 2D and S3). Complex V subunits
encoded by nDNA were similarly expressed in the two groups,
whereas we measured a large difference for the corresponding
mtDNA-encoded ones (Figures 2E and S3). Overall, these results
indicate that COX fibers have a reduced expression of mtDNA-
encoded proteins compared to COX+ (Figure 2F). Accordingly,
COX+ fibers of CPEO patients were shown to contain more
copies of mtDNA than COX fibers (Greaves et al., 2010). We
then looked at the assembly factors of mitochondrial complexes,
which were slightly higher in COX than in COX+ fibers for all of
the complexes but ATP synthase. Only 2 assembly factors of
complex I (AIFM1, NDUFAF7) and 3 of complex IV (SCO1,
COX15, COA7) showed significant differences (p < 0.05) (Fig-
ure S4A). Citrate synthase (CS), a classical marker of mitochon-
drial content, was 36% higher in COX fibers (Figure S4B).
Next, we asked whether COX fibers show increased mito-
chondrial biogenesis compared to COX+ fibers, matching light
and electron microscopy where signs of increased biogenesis
(ragged red fibers [RRFs]) are more frequent and more marked
in COX than in COX+ fibers (DiMauro and Schon, 2003). To
this end, we curated a list of human proteins involved in29, 3825–3834, December 17, 2019 3827
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Figure 3. Differences between COX+ and COX Muscle Fiber Pools at Whole Proteome and Mitochondrial Proteome Levels
(A) Volcano plot of statistical significance against fold change, showing the most significantly different proteins between COX+ (orange circles) and COX fibers
(blue circles) in the whole cell proteome. Analysis performed in 5,940 proteins quantified at least once in these samples. Filled circle, mitochondrial proteins.
(B) Hierarchical clusters of mitochondrial proteins (normalized by citrate synthase) with significantly different expression in COX+ and COX fiber pools of each
patient (labeled P1, P2, P3). Color scale (Z scored expression) at the bottom. Each sample is the mean of technical triplicates; missing values were imputed.
Cluster separation is shown in color at left.
(C) Bar graphs showing fold increase of the top 3 annotation enrichments of mitochondrial proteins with significantly higher expression in COX and COX+ fiber
pools (Fisher’s exact test, false discovery rate [FDR] 0.02). Test p value is reported on top of each bar.
See also Figure S5 and Tables S7, S8, and S9.mitochondrial biogenesis based on the literature (Permuth-Wey
et al., 2011). Of those, we could quantify 15 proteins in at least
2 samples per group (COX versus COX+). Three proteins (tran-
scription termination factor 4, MTERF4; constitutive nitric oxide
synthase, NOS1; and the delta subunit of calcium/calmodulin-
dependent protein kinase type II, CAMK2D) were significantly
higher expressed in COX fibers, while 2 proteins (mitogen-
activated protein kinase 1, MAPK1; AMP kinase [AMPK] subunit
alpha-2, PRKAA2) were significantly higher expressed in COX+
fibers (Table S6). Other critical regulators of mitochondrial
biogenesis were, however, not significantly changed (e.g., tran-
scription factor A, mitochondrial [TFAM]) or could not be quanti-3828 Cell Reports 29, 3825–3834, December 17, 2019fied at all (e.g., peroxisome proliferator-activated receptor
gamma co-activator 1alpha [PGC1alpha], CAMK4).
Adaptive Molecular Responses to Mitochondrial
Dysfunction at the Cellular Level
The expression of many respiratory chain components was
significantly higher in COX+ than in COX fibers (volcano plot,
Figure 3A). COX fibers overexpressed most significantly
UTP18, a nucleolar protein involved in ribosomal processing
RNA under stress conditions (Yang et al., 2015). The cardioli-
pin-binding protein STOML2/SLP2 was also upregulated in
COX fibers (Figure 3A). STOML2 forms a complex with the
fusion-promoting guanosine triphosphatase (GTPase) mitofusin
2 (MFN2) enhancing mitochondrial biogenesis (Christie et al.,
2011; Ha´jek et al., 2007).
We used MitoCarta 2.0 (Calvo et al., 2016) to select the mito-
chondrial proteins from the dataset (see Bioinformatic and
statistical analysis). We normalized mitochondrial protein
expression by CS expression. We could thus analyze the pro-
teomes of COX+ and COX fiber pools, correcting for systematic
differences of mitochondrial content between patients and sam-
pling differences. t Test comparison showed 148 proteins with
significantly different expression between the two groups (p <
0.05). Unsupervised hierarchical clustering separated COX+
and COX fibers, revealing enriched GO and keyword terms
(Figure 3B; Table S7). COX+ showed >40-fold enrichments in
respiratory chain annotations. COX displayed significant en-
richments (>25-fold) in mitochondrial ribosomes (Figure 3C).
This may be a compensatory mechanism for the defective
expression and function of the respiratory chain in COX fibers
(see Discussion).
Other cell compartments showed a smaller difference be-
tween COX+ and COX fibers. We selected the proteins located
in the endoplasmic reticulum (ER) using keyword annotations,
which yielded 317 proteins that could be quantified in both fiber
groups. Fourteen proteins were significantly more expressed in
COX fibers and 21 in COX+, among them the ER shaping
proteins RTN4 (4.6-fold higher in COX+, p < 105) and ATL2
(1.8-fold higher in COX, p < 0.05). Two proteins induced during
ER stress and the unfolded protein response (UPR), SEC63
and ERO1LB, were also significantly higher in COX fibers, sug-
gesting a partial activation of this pathway (Figure S5A). The
chaperone HSPA5/grp78, a major UPR player, was expressed
1.7-fold higher in COX than in COX+ fibers, although the differ-
ence was not significant (p = 0.06) (Figure S5A). We also looked
at non-blood-related inflammatory markers (GO Biological Pro-
cess [GOBP] inflammatory response) as readout of muscle dam-
age. Three proteins were expressed at a significantly higher level
in COX+ fibers (IKBKG/NEMO, RPS6KA4, JMJD7) and two in
COX fibers (APOL2, PLGRKT), indicating no strong activation
of this pathway in the fibers of our patient cohort (Figure S5B).
To elucidate the effects of mitochondrial disease on the prote-
ome of individual CPEO patients, we compared the COX+ and
COX fibers of each patient. t Test analysis retrieved 182, 34,
and 122 proteins with significantly higher expression in the
COX+ fiber pools of patients 1, 2, and 3, respectively (Figure 3;
Table S8; STARMethods).We constructed a Venn diagram high-
lighting 11 proteins upregulated in all 3 patients and >50-fold
enriched in respiratory chain terms (Figure S5C). The same pro-
cedure in COX+ fibers highlighted various annotations of energy
metabolism in patients 1 and 3, as well as the enrichment in
cysteine oxidation in patient 2. The proteins with significantly
higher expression in COX fibers amounted to 22, 177, and 92
in the 3 patients, respectively (Figure 3; Table S9; STAR
Methods). Only C1QBP/p32 (component 1 Q subcomponent-
binding protein) was upregulated in COX fibers of all of the pa-
tients. C1QBP is a ubiquitous protein of poorly characterized
function localized predominantly in the matrix. Approximately
70% of proteins significantly overexpressed in COX fibers
were specific for 1 patient only. A common feature of patients1 and 3 was the enrichment in the TCA cycle, possibly an indica-
tion of the increased usage of the Krebs cycle to alleviate
malfunctioning of the respiratory chain (Figure S5D). Such het-
erogeneity is likely causing different responses to therapeutic
interventions.
Mitochondrial Disease at the Single-Fiber Level
Human slow-type 1 fibers are characterized by oxidative meta-
bolism and more mitochondria than the fast-type 2A and 2X
fibers, which have a higher expression of glycolytic enzymes
(Murgia et al., 2017). Comparing pure fiber types can thus
precisely pinpoint the specific disease pathogenesis at the sin-
gle-cell level. To this aim, we cut 40 cross-sections of 10-mm
thickness from muscle biopsies of 3 patients, histochemically
stained every second section as a morphological reference,
and excised 20 serial sections of individual fibers using LCM
(Figure 1A). With this procedure, each single fiber encompasses
400 mm of tissue. The serial sections of the same fiber were
pooled and processed together for MS analysis. We isolated
three COX+ and three COX single fibers from each patient.
MS-based proteomics allowed us to directly quantify different
myosin isoforms and thus determine the fiber type (Table S5)
(Murgia et al., 2015). Of 18 single fibers, 13 were pure slow-
type 1, as defined by the predominant expression of MYH7, 3
were pure fast fibers expressing a majority (>75%) of MYH2A,
and 3 were mixed 1/2A type (Figure 4A). To confirm the precision
of fiber type assignment, we selected the proteins involved in
contraction (keyword annotation ‘‘muscle protein’’), which are
typically expressed in a fiber type-specific manner. Hierarchical
clustering divides the fibers assigned as fast from those as-
signed as slow. Among the proteins characterizing the two
main clusters are myosin and troponin isoforms, specifically
segregating into fast and slow gene products (Figure 4B).
Precise fiber type assignment allowed us to focus on the prote-
ome-wide effects of mitochondrial disease in a fiber type-
specific manner. We averaged protein expression in all of the
slow fibers of each patient, which yielded a separation by PCA of
COX+ and COX fibers along component 3, driven by a significant
enrichment (p < 1012) in respiratory chain components inCOX+ fi-
bers (Figure4C).SerpinB3,amajordriverof theseparationofCOX
slow fibers, is a serine protease inhibitor upregulated by oxidative
stress (Ciscato et al., 2014). Combined with a high expression of
the nicotinamide nucleotide transhydrogenase (NNT), this indi-
cates that COX slow fibers cope with high levels of reactive oxy-
gen species. NNT is expressedmore in slow than in fast fibers and
is involved in NADPH generation, thus contributing to the buffering
of H2O2 production (Schiaffino et al., 2015) (Figure 4D).
A t test comparison between the mitochondrial proteomes of
COX+ andCOX slow fibers yielded 50 significant proteins. As ex-
pected, the 22 proteins with higher expression in COX+ were en-
riched in oxidative phosphorylation terms (p < 1010). The 28 pro-
teins that were more abundant in COX fibers had various intra-
mitochondrial localizations, but formed a highly interconnected
network of functional association with two main clusters, as re-
vealed by the STRING database (Szklarczyk et al., 2015) (Fig-
ure 4E). One functional cluster highlighted by this analysis is en-
riched in pyruvate dehydrogenase (p < 106) and TCA cycle
annotations (p < 1010). The other major cluster is enrichedCell Reports 29, 3825–3834, December 17, 2019 3829
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in chaperones (GO Molecular Function Unfolded Protein Binding,
p < 106) and includes major players of cristae remodeling, such
as OPA1, the MICOS complex subunit IMMT, the scaffolding pro-
teins PHBandPHB2, and proteases such as LONP1andAFG3L2,
important for quality control, which were all >1.8-fold higher in
COX fibers (Table S10) (Baker et al., 2019). We extended this
analysis by curating a list of 30 proteins involved in mitochondrial
dynamics and cristae remodeling and quantifying their expression
in COX and COX+ fiber pools. Twelve proteins had >1.5-fold
higher expression in COX than in COX+ fibers, whereas only 2
were >1.5 higher in COX+ fibers. Among the latter is DNM1L/
DRP1, a master regulator of fission. In addition to the protease
AFG3L2 and the MICOS complex protein IMMT, the protease
YME1L1 was significantly higher in COX fiber pools (p < 0.001)
(Table S11).
Finally, we compared the effects of mitochondrial disease at
the proteome level in single slow and fast fibers from the same
patient. The 4 slow fibers and 2 fast fibers obtained from patient
1 (see Figure 4A) could be separated by principal-component
analysis (PCA) along component 1 into COX+ and COX groups.
Furthermore, slow and fast fibers were clearly distinguished
along component 2, driven by key determinants of fiber types
such as myosin and troponin isoforms (Figures 4F and 4G). We
then directly compared the expression of individual metabolic
pathways in the 4 slow and 2 fast fibers from patient 1. Both
COX+ slow fibers had a higher expression of the respiratory chain
complex I than the corresponding COX fibers. This difference
could be observed at generally lower expression levels also in
the two fast fibers, which contain fewer mitochondria than
slow fibers (Figure 4H). By measuring the expression of respira-
tory chain components in COX+ and COX single fibers of the
same patient, here, we quantify the net effect of disease onmito-
chondrial protein expression in a fiber type-specific manner,
devoid of variability among individuals. Regulated proteins
were indeed different between slow and fast fibers of the same
individual. Measuring the COX+:COX expression ratio, we
observed 62% similarity between the fast and slow fibers of pa-
tient 1. Conversely, 38% of the measured proteome was differ-Figure 4. Single Fiber Features and Fiber Type Specificity in Mitochon
(A) Expression of 4 adult isoforms of myosin heavy chain (MYH) in 6 individual fibe
intensities of MYH7 (characterizing type 1/slow fibers), MYH2 (characterizing
(characterizing rodent type 2B/fast fibers and only present in trace amounts in hu
type 1/slow fibers. Fast fibers are marked by an asterisk.
(B) Hierarchical clustering of proteins involved in muscle contraction, showing cl
(C) Principal-component analysis (PCA) of mitochondrial proteins of pure slow si
segregate into COX+ (orange) and COX (blue) along component 2.
(D) Loadings of the PCA showing major drivers of separation and significant e
significantly higher expression in COX fibers are marked with a black line.
(E) Functional interaction network analysis of proteins with significantly higher e
chondrial localization; box size reflects p value in the COX+ versus COX t test a
STRING database. Proteins significantly overexpressed in COX fibers but withou
right. Annotation enrichments with p value are marked in the green areas.
(F) PCA of all single fibers isolated from patient 1. Dots mark slow fibers and squ
(G) PCA loadings showing drivers of the segregation into component 1 (separatin
type). The yellow area highlights fast fiber type-specific proteins, such as fast tro
(H) Heatmap of normalized protein expression (Z scored, scale at bottom) in singl
and 2 fast fibers, 1 COX and 1 COX+, respectively. Only proteins expressed in all
TCA cycle, and fatty acid oxidation are shown. Gray squares, not quantified.
See also Figures S5 and S6 and Tables S5, S10, and S11.ently regulated in the 2 fiber types (21% higher in fast, 17%
higher in slow) (Figure S6). Glycolytic enzymes were higher in
fast fibers independent of COX status, indicating that the upre-
gulation of glycolysis is not a common compensation mecha-
nism for energy deficit in COX fibers. Conversely, TCA cycle
enzymes were similarly overexpressed in COX fibers, regard-
less of fiber type. This pathway is likely a fiber type-independent
compensatory mechanism for the respiratory chain deficiency in
the patient. We then focused on fatty acids beta-oxidation, con-
firming that this pathway has higher expression in the mitochon-
dria of slow fibers than in those of fast fibers (Murgia et al., 2015).
Bioenergetic deficiency in COX slow fibers was associatedwith
the further upregulation of fatty acid oxidation enzymes, which
was essentially negligible in fast fibers (Figure 4H).
DISCUSSION
Mitochondrial disorders, in a strict sense, are the consequence
of mutations affecting the respiratory chain. They frequently hit
skeletal muscle, while other tissues are involved in a disease-
specific manner. The overall relation between mtDNA mutations
and clinical presentation is complex and poorly characterized at
the molecular level. A diagnostic marker is the appearance of
RRFs reflecting metabolic decompensation above a certain
threshold of mutant mtDNA (heteroplasmy). Deeper insight into
the underlyingmolecular mechanisms is needed to better under-
stand the pathogenesis of mitochondrial disorders. To provide
mechanistic details, this analysis needs a combination of fine tis-
sue dissection and large-scale technologies.
Our workflow allowed the quantification of >2,000 proteins
from minute amounts of patient material in just 2 h of measure-
ment time. We could clearly show significantly higher expression
of respiratory chain components in COX+ than in COX fibers.
Conversely, assembly factors of complexes I–IV were higher in
COX fibers as compared to COX+ fibers, some of them statisti-
cally significant (Figure S4), which may indicate a compensatory
mechanism. The difference in the expression of mitochondrial
biogenesis factors was surprisingly small between COX anddrial Myopathies
rs (labeled A, B, and C for both COX and COX+) of each patient. The summed
type 2A/fast fibers), MYH1 (characterizing type 2X/fast fibers), and type 2B
mans) were used as 100%. Fibers with >75% of MYH7 were considered pure
uster segregation of fast and slow specific isoforms.
ngle fibers. Fibers from 3 patients (average of all slow fibers of each individual)
nrichments (arrow and corresponding p value). Mitochondrial proteins with
xpression in COX slow fibers. Fibers are color-coded based on intra-mito-
nd line thickness marks the functional interaction confidence as defined in the
t known functional interactionswith the rest of the network are shown at bottom
ares mark fast fibers, based on the MYH quantifications shown in (A).
g COX+ and COX fibers) and component 2 (separating fibers based on fiber
ponins. The corresponding slow isoforms are highlighted in green.
e fibers from 1 patient, 4 slow fibers in total (2 COX+ and 2 COX, as indicated)
of the fibers were used for the analysis. Respiratory chain complex I, glycolysis,
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COX+ fibers (Table S6). This is in contrast to light and electronmi-
croscopy, in which signs of increased biogenesis (RRFs) are
more frequent and more marked in COX than in COX+ fibers
(DiMauro and Schon, 2003).
Our results show that COX+ and COX fibers are significantly
different at the proteome level. COX fibers upregulated
mitochondrial ribosomes and proteins involved in the control of
translation (Figure 3). Among these, C1QBP, upregulated in the
COX fibers of all of the patients (Figure S4), is required for func-
tional mitoribosome formation and protein synthesis (Yagi et al.,
2012). Mutations in C1QBPwere described in patients with mito-
chondrial cardiomyopathy and combined respiratory chain
enzyme deficiency (Feichtinger et al., 2017).
COX fibers also upregulate mitochondrial chaperones and
STOML2 (Figure 3). The latter organizes cardiolipin-enriched
microdomains in the inner membrane and controls the assembly
of functional respiratory supercomplexes (Mitsopoulos et al.,
2015). We measured a significant increase of several members
of the OPA1-dependent cristae remodeling program in COX
single slow fibers, suggesting that they may be producing
more cristae. Ultrastructural analyses of patients with CPEO
and other mitochondrial disorders show several morphological
abnormalities, such as extended ‘‘onion-like’’ concentric cristae
and ‘‘donut mitochondria,’’ indicating elongation and hyper-
branching (Bacalhau et al., 2018; Vincent et al., 2016). Because
the ultimate effects of mtDNA mutations will reflect on the fiber
metabolic profile, it would be interesting to carry out a metabo-
lomic analysis of COX+ and COX fibers following the technolog-
ical progress of this field.
A novelty of our proteomic approach is the ability to analyze
mitochondrial disease in individual fibers, by following and cut-
ting the same fiber across 20 serial sections. Skeletal muscle
has a heterogeneous composition in slow type 1 and fast type
2 fibers, with different mitochondrial content. In the context of
mitochondrial disorders, fiber type composition is superimposed
onto the pathological process giving rise to the COX+ and COX
fiber mosaic. To reduce the variables causing this extreme het-
erogeneity, we selected a pool of single fibers that were type
1 slow based on the expression of MYH7, the slow myosin
heavy-chain isoform (Figure 4). We thus eliminated the con-
founding effects of the heterogeneous fiber type composition,
revealing a coordinated increase of a network of functionally
interacting proteins involved in mitochondrial dynamics and
quality control. We found that eight of these proteins were ex-
pressed at a significantly higher level in COX than in COX+
slow fibers. We observed a significant upregulation of the
OPA1-dependent cristae remodeling program in COX slow fi-
bers. This pathway controls the tightening of mitochondrial
cristae, which results in higher respiratory efficiency and limits
the production of reactive oxygen species and cytochrome c
release (Varanita et al., 2015). Comparing fibers from the same
patient, we showed that the upregulation of TCA cycle enzymes
occurs in both fast and slow COX fibers and likely represents a
fiber type-independent compensatorymechanism for the energy
deficit caused by disease. Only COX slow fibers, however, up-
regulated the enzymes involved in fatty acids beta-oxidation.
Our single fiber analysis has thus uncovered a fiber type-specific
metabolic shift induced by mitochondrial disease.3832 Cell Reports 29, 3825–3834, December 17, 2019It remains to be determined whether the combination of the
observed compensatory mechanisms ultimately provides a relief
from the energy imbalance caused by respiratory chain defect or
whether it contributes to the pathogenesis of the disease by
causing proteotoxic stress and mitochondrial integrated stress
response. It will also be of interest to assess the role of FGF21,
a recently characterized mediator of mitochondrial stress
responses, in the proteomic rearrangements that we have
measured in COX fibers (Forsstro¨m et al., 2019). Predicting
the outcome of adaptive responses in mitochondria has tradi-
tionally proven extremely complex. In contrast to CPEO and
most related disorders, in which RRFs are mostly COX, muscle
from MELAS patients shows predominantly COX+ RRFs. The
fact that respiratory activity was more severely compromised
in MELAS than in CPEO patients by 31P magnetic resonance
(MR) spectroscopy in one study (Liu et al., 2014) led to the
hypothesis that increased COX expression may worsen the
phenotype by impinging on the catabolism of nitric oxide (Balke
et al., 2019). This hypothesis, however, did not take into account
the predominant complex I defect in MELAS. In CPEO, it is clear
that higher proportions of mtDNA deletion lead to higher
numbers of COX fibers and to less bioenergetic activity (Geller-
ich et al., 2002).
In conclusion, metabolic decompensation in COX fibers is
accompanied by an extensive rearrangement of the mitochon-
drial proteome. This involves the upregulation of metabolic
pathways possibly serving as compensatory mechanisms for
the bioenergetic deficit causing the disease, as well as of chap-
erones, reactive oxygen species (ROS) scavengers, and proteins
that control inner membrane architecture and supercomplex
formation. Further technological developments leading to a sys-
tems view of mitochondrial proteome remodeling at the muscle
fiber level will be instrumental for the development of targeted
therapies for mitochondrial disorders.STAR+METHODS
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Biological Samples
Cultured human myoblasts mitoNET Biobank http://mitonet.org
Muscle biopsies mitoNET Biobank http://mitonet.org
Chemicals, Peptides, and Recombinant Proteins
Cytochrome c (equine recombinant, expressed
in E. coli)
Sigma Cat# C-2506
Diaminobenzidine tetrahydrochloride Sigma Cat# D-5637
Sodium succinate Sigma Cat# S-2378
Sodium azide Sigma Cat# BDH30111
Nitroblue tetrazolium Sigma Cat# N6876
Eukitt Sigma Cat# 03989
Catalase Sigma Cat# C-9322
PBS (0.2M, Ph7.5) Sigma Cat# P0014
PBS (0.1M, Ph7.4) Sigma Cat# P0008
Phenazine methosulphate Sigma Cat# P9625
Chloracetamide Sigma Cat# C0267
Trypsin Sigma Cat# T6567
Lysyl Endopeptidase (Lys-C) Wako Chemicals Cat# 125-05061
Sodium deoxycholate Thermo Fischer Scientific Cat# 89904
TCEP (tris(2-carboxyethyl)phosphine) Thermo Fischer Scientific Cat# PG82090
Acetonitrile Thermo Fischer Scientific Cat# 100029
Ammonia Thermo Fischer Scientific Cat# 533003
Formic acid Thermo Fischer Scientific Cat# 533002
Deposited Data
Proteomic dataset with raw and processed data This paper ProteomeXchange PXD010489
Software and Algorithms
MaxQuant Cox and Mann, 2008 https://www.maxquant.org/
Perseus Tyanova et al., 2016b https://maxquant.org/perseus/
Other
Laser capture microdissection system Leica LMD 7000
Loss-less Nano-fractionator PreOmics, Kulak et al., 2017 Spider fractionator
Leica Membrane Slides ª PEN membrane 2.0 mm Micro Dissect Gmbh (Herborn) Cat# 11505158
Slides superfrost Menzel GmbH Cat# 7201277
Coverslips IDL (Nidderau) Cat# 190002450
0.5ml Laser capture microdissection -Tube Thermo Fischer Scientific Cat# AB-0350
FastPrep-24 homogenizer MP Biomedicals https://eu.mpbio.com/fastprep-24-5g-instrument
Bioruptor Diagenode https://www.diagenode.com/en
Nanodrop 2000 Spectrophotometer Thermo Fischer Scientific https://www.thermofisher.com/us/en/home.htmlLEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Thomas Klopstock
(tklopsto@med.lmu.de). This study did not generate new unique reagents.Cell Reports 29, 3825–3834.e1–e4, December 17, 2019 e1
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Patients, study design and approvals
All of the muscle specimens and myoblast cells were obtained from the biobank of the German network for mitochondrial disorders
(mitoNET) at the Friedrich-Baur-Institute. The research project was approved by the Ethics Committee of the LMUMunich (N. 198-15)
and the study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. Muscle
biopsies had been obtained for diagnostic purposes and written informed consent had been obtained from the patients. For the
study, we randomly selected 3 patients with CPEO, defined by the pathognomonic clinical phenotype, the presence of RRF on mus-
cle biopsy and detection of a mtDNA deletion (Table S4). All patients were of European origin, two males (age 38 and 49) and one
female (age 32). Diagnostic specimens had been collected from the right deltoid or left quadriceps muscle by open biopsy, frozen
in liquid nitrogen and stored at 80C. The control myoblast cells used for the library were randomly selected from 3 patients
with no known mitochondrial disorder.
Cell culture
Primary cell lines of human myoblasts used for the peptide library were isolated from muscle biopsies of individuals without known
mitochondrial disease and grown in DMEM supplemented with penicillin/streptomycin, L-glutamine, and 10% FBS. A pool of three
cell lines (from male and female patients) was used for the peptide preparation.
METHOD DETAILS
Tissue preparation for cryosectioning
Muscle specimens were transferred in liquid nitrogen to the cryostat. Alternate serial sections (10 mm) were adhered to Superfrost
plus microscope slides for histochemical staining and to membrane slides for laser microdissection. Superfrost plus slides were
air-dried for about 24h and then stored at 20C for the next histochemical staining. The membrane slides were stored at 80C
prior to cutting and processing for MS-based proteomics.
Sequential cytochrome c oxidase / succinate dehydrogenase (COX/SDH) histochemistry
Slides were allowed to dry at room temperature for 10 min and processed according to standard protocol (Old and Johnson, 1989).
For COX staining, sections were incubated in COX medium (100 mM cytochrome c, 4 mM diaminobenzidine tetrahydrochloride,
and 20 mg/ml catalase in 0.2 M phosphate buffer, pH 7.0) for 90 min at 37C. Sections were then washed in standard PBS,
pH 7.4 (23 5min) and incubated in SDHmedium (130mMsodium succinate, 200 mMphenazinemethosulphate, 1mMsodium azide,
1.5 mM nitroblue tetrazolium in 0.2 M phosphate buffer, pH 7.0) for 120 min at 37C. Sections were then washed in PBS, pH 7.4 (23
5min), rinsed in distilled water and dehydrated in an increasing ethanol series up to 100%, prior to incubation in xylene andmounting
in Eukitt.
Laser capture microdissection (LCM)
The procedure was carried out essentially as we described previously (Koob et al., 2012). The images of whole COX/SDH-stained
slides and sections of interest were acquired and stored using a Leica LMD 7000 System. Next, we observed the unstained serial
sections under the microscope at various magnifications and compared with the pictures of stained sections individually. According
to the recognizable histochemical features of COX+ and COX- cells, we determined the coordinates of their corresponding unstained
cells and dissected them by LCM. 100 COX+ and 100 COX- cells were dissected for each patient. Similarly, we selected 3 COX+ and
3 COX- single fibers with clearly recognizable histochemical features for each patient, then excised 20 COX+ or 20 COX- serial sec-
tions for each fiber separately. The whole procedure was precisely timed for each sample and carried out in less than 30 min at room
temperature. Fiber sections were captured by cutting the region of interest onto the caps of 0.5ml Thermo-Tube, whichwere carefully
closed and immediately frozen in liquid nitrogen at the end of the procedure. Samples were stored at 80C until used. Protein
amount was determined in serial dilutions of fiber section pools resuspended in 8 M urea containing 10 mM Tris-HCl, pH 8.5,
measuring the fluorescence emission of tryptophan (excitation 280 nm, emission 350 nm).
Peptide preparation from muscle fiber sections, total muscle lysate and myoblasts
Fiber sections were resuspended in 10 ml of sodium deoxycholate (SDC)-based reduction and alkylation buffer by extensively
washing the collection tube after laser capture. Total muscle (60 mg) was crushed in liquid nitrogen using a mortar and pestle.
Powderedmuscle samples andmyoblast cells (3x 106 cells) were resuspended in 310 ml (5 ml/mg) and 200 ml SDCbuffer, respectively.
The total muscle sample was further mixed (six times 30 s and cooled on ice in between) using a FastPrep-24 Instrument (MP Bio-
medicals). Samples were further boiled for 10 min to denature proteins (Kulak et al., 2014).
For total muscle andmyoblast lysate (not for sections), protein concentration wasmeasured using the Tryptophan assay. Themus-
cle sections (entire sample) were digested with 0.5 mg of trypsin and 0.5 mg of LysC per sample at 37C, under continuous stirring. For
total muscle lysate and myoblasts, 250 mg were digested overnight with Lys-C and trypsin in a 1:25 ratio (mg of enzyme to mg of pro-
tein) at 37C, under continuous stirring. On the following day, samples were sonicated using a Bioruptor (Diagenode, 15 cycles ofe2 Cell Reports 29, 3825–3834.e1–e4, December 17, 2019
30 s) and further digested for 3 hwith Lys-C and trypsin (1:100 ratio). Peptides were acidified to a final concentration of 0.1% trifluoro-
acetic acid (TFA) for SDB-RPS binding and 40 mg of peptides were loaded on four 14-gauge Stage-Tip plugs. Peptides were washed
first with wash buffers (P.O. 00001, PreOmics GmbH) using an in house made Stage-Tip centrifuge at 2000 x g. Peptides were eluted
with 60 ml of elution buffer (80% acetonitrile / 1% ammonia) into auto sampler vials and dried using a SpeedVac centrifuge (Eppen-
dorf, Concentrator plus). Peptides were resuspended in 2% acetonitrile / 0.1% TFA before peptide concentration estimation using a
Nanodrop spectrophotometer (Thermo Fischer Scientific). Purified peptides from total muscle and myoblast lysates were further
subjected to fractionation.
High pH reversed-phase fractionation
We applied a pre-fractionation based on a high pH buffer system and resulting in an orthogonal separation to the online LC that is
directly coupled to the MS. High pH reversed-phase fractionation has been shown to be particularly powerful to achieve deep pro-
teomic libraries. We used the Spider fractionator device (PreOmics), a software-controlled rotor valve-based fraction collector
coupled to a nanoflow HPLC (EASY-nLC 1000 system, Thermo Fisher Scientific), which enables the fractionation of minute amounts
of material without sample loss. Here, we fractionated a total of 40 mg of purified and digested peptides that was automatically
concatenated into 16 fractions using a rotor valve shift of 90 s. About 0.5 mg of each fraction were subjected to the subsequent
LC-MS/MSmeasurements. The pre-fractionation procedures and the concatenation scheme underlying the construction of the Spi-
der instrument have been described by us in detail (Kulak et al., 2017).
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) analysis
Nanoflow LC-MS/MS analysis of tryptic peptides was conducted on a Q Exactive HF Orbitrap coupled to an EASYnLC 1200 ultra-
high-pressure system via a nano-electrospray ion source (all from Thermo Fisher Scientific). Peptides were loaded on a 50 cmHPLC-
column (75 mm inner diameter; in-house packed using ReproSil-Pur C18-AQ 1.9 mm silica beads; Dr. Maisch). Peptides were
separated using a linear gradient from 2% B to 20% B in 55 min and stepped up to 40% in 40 min followed by a 5 min wash at
98% B at 350 nl/min where solvent A was 0.1% formic acid in water and solvent B was 80% acetonitrile and 0.1% formic acid in
water. The gradient was followed by a 5 min 98% B wash and the total duration of the run was 100 min. Column temperature
was kept at 60C by a Peltier element-containing, in-house developed oven.
The mass spectrometer was operated in ‘‘top-15’’ data-dependent mode, collecting MS spectra in the Orbitrap mass analyzer
(6000 resolution, 300-1650 m/z range) with an automatic gain control (AGC) target of 3E6 and a maximum ion injection time of
25 ms. The most intense ions from the full scan were isolated with an isolation width of 1.5 m/z. Following higher-energy collisional
dissociation (HCD), MS/MS spectra were collected in the Orbitrap (15000 resolution) with an AGC target of 5E4 and a maximum ion
injection time of 60 ms. Precursor dynamic exclusion was enabled with a duration of 30 s.
QUANTIFICATION AND STATISTICAL ANALYSIS
Computational proteomics
TheMaxQuant software (version 1. 6.0.12) was used for the analysis of raw files. Peak lists were searched against the human UniProt
FASTA reference proteomes version of 2016 as well as against a common contaminants database using the Andromeda search en-
gine (Cox and Mann, 2008; Cox et al., 2011). Carbamidomethyl was included in the search as a fixed modification, oxidation (M) as
variable modifications. The FDRwas set to 1% for both peptides (minimum length of 7 amino acids) and proteins and was calculated
by searching a reverse database. Peptide identification was performed with an initial allowed precursor mass deviation up to 7 ppm
and an allowed fragment mass deviation 20 ppm. For the relative quantification of MYH isoforms, only peptides unique to each iso-
form were used for protein quantification in MaxQuant. The relative expression of each MYH isoform is calculated as percent of the
summed intensity of the four adult isoforms (MYH1, MYH2, MYH4, MYH7).
Bioinformatic and statistical analysis
The Perseus software (version 1.5.4.2), part of the MaxQuant environment (Tyanova et al., 2016b), was used for data analysis and
statistics. Categorical annotations were provided in the form of UniProt Keywords, KEGG and Gene Ontology. Mitocarta2 scores
were provided as numerical annotations (x > 1). Label free quantification (MaxLFQ) was used for protein quantification in all exper-
iments, using Z score where indicated (Cox et al., 2014). When using pools of COX+ and COX- sections from individual patients, 100
sections were pooled, the peptides were purified and analyzed by MS in technical triplicates. This was performed in three different
patients (i.e., biological triplicates, each in technical triplicates, for COX+ and COX- respectively). For the single fiber analysis, three
single COX+ and three single COX- fibers were isolated from each patient (i.e biological triplicates in three patients for COX+ and
COX- respectively). Comparison of quantitative parameters between the two groups was performed using Student’s t-test. P-value
below 0.05 was considered significant. Normalization for mitochondrial content was performed dividing expression values of each
sample by the corresponding expression of citrate synthase (CS). PCA and cluster analysis was performed in the Perseus software
using logarithmic expression values of LFQ. For hierarchical clustering, LFQ intensities were Z-scored and clustered using Euclidean
distance for column and row clustering. The t test for the volcano plot was carried out using FDR 0.05 and 250 randomizations.
Where indicated, missing values were imputed by using random numbers from a normal distribution to simulate the expression ofCell Reports 29, 3825–3834.e1–e4, December 17, 2019 e3
low abundant proteins. We used awidth parameter of 0.3 of the standard deviation of all values in the dataset with a down shift by 1.8
times this standard deviation. Pathway enrichment analysis was performed using Fisher exact test with a Benjamini-Hochberg FDR
cutoff of 0.02.
DATA AND CODE AVAILABILITY
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the partner repository with
the dataset identifier PXD010489.
Network analysis
Functional interaction network analysis was performed using the protein-protein interaction database STRING (version 11.0). We
used medium confidence (0.4), one shell of interactors and filtered interactions keeping the ones derived from experiments, textmin-
ing, database and coexpression. Protein localization was manually curated and the DAVID Bioinformatics resources (version 6.8)
were used for enrichment analysis (Jiao et al., 2012).e4 Cell Reports 29, 3825–3834.e1–e4, December 17, 2019
